PTGX CEO sells 75K shares after option exercise

Protagonist Therapeutics President and CEO Dinesh V. Patel reported an exercise-and-sale transaction involving 75,000 shares of common stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

4/A

Rhea-AI Filing Summary

Protagonist Therapeutics President and CEO Dinesh V. Patel reported an exercise-and-sale transaction involving 75,000 shares of common stock. On May 12, 2026, he exercised stock options for 75,000 shares at $21.58 per share and sold 75,000 shares in open-market trades at a weighted average price of $100.12 per share, with individual sale prices ranging from $98.83 to $103.50. After these transactions, he directly holds 523,478 common shares. The filing notes the actions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on January 30, 2026, and that the related stock options are fully vested and expire on October 11, 2026, with 225,000 options reported as remaining outstanding.

Insider Trade Summary 10b5-1

Exercise and Sale: 75,000 shares ($5.89M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider PATEL DINESH V PH D

Role President and CEO

Sold 75,000 shs ($7.51M)

Approx. gross sale proceeds $7.51M

Approx. exercise cost $1.62M

Approx. pre-tax spread $5.89M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	75,000	$0.00	$0.00
Exercise	Common Stock	75,000	$21.58	$1.62M
Sale	Common Stock	75,000	$100.12	$7.51M

Holdings After Transaction: Stock Option (right to buy) — 225,000 contracts (Direct); Common Stock — 523,478 shares (Direct)

Footnotes (3)

F1. This Form 4 Amendment is being filed to clarify that the transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026 and to check the appropriate box which appeared unchecked on the original Form 4 filing.
F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.83 to $103.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3. These stock options are fully vested and will expire on October 11, 2026.

Key Figures

Shares sold: 75,000 shares Average sale price: $100.12 per share Sale price range: $98.83–$103.50 per share +4 more

7 metrics

Shares sold 75,000 shares Open-market sale on May 12, 2026

Average sale price $100.12 per share Weighted average for 75,000 shares sold

Sale price range $98.83–$103.50 per share Individual trade prices on May 12, 2026

Option exercise price $21.58 per share Conversion price for 75,000 options exercised

Shares held after 523,478 shares Direct PTGX common stock holdings post-transaction

Remaining options 225,000 options Stock options outstanding after exercise, expiring Oct 11, 2026

10b5-1 plan adoption date January 30, 2026 Plan governing the May 12, 2026 transactions

Key Terms

Rule 10b5-1 plan, open-market sale, Stock Option (right to buy), weighted average sale price, +1 more

5 terms

Rule 10b5-1 plan regulatory

"transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (right to buy) financial

"security_title": "Stock Option (right to buy)""

weighted average sale price financial

"The price reported represents the weighted average sale price per share."

fully vested financial

"These stock options are fully vested and will expire on October 11, 2026."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PTGX CEO Dinesh Patel report on this Form 4/A?

Dinesh V. Patel reported exercising options for 75,000 PTGX shares and selling 75,000 shares in open-market trades. This combined exercise-and-sale pattern reflects option conversion followed by share disposals, rather than a direct open-market share purchase.

At what prices did the PTGX CEO sell the 75,000 shares reported?

The CEO sold 75,000 PTGX shares at a weighted average price of $100.12 per share. Individual trades occurred at prices between $98.83 and $103.50, with full price-breakdown details available to regulators or shareholders upon request.

How many Protagonist Therapeutics shares does the CEO hold after this transaction?

Following the reported transactions, the CEO directly holds 523,478 PTGX common shares. This figure reflects his remaining equity stake after exercising options for 75,000 shares and selling 75,000 shares on May 12, 2026, as disclosed in the Form 4/A.

Were the PTGX CEO’s May 12, 2026 trades made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on January 30, 2026. Such pre-arranged plans schedule trades in advance, helping separate routine liquidity events from discretionary market-timing decisions.

What are the key details of the PTGX stock options exercised by the CEO?

The CEO exercised stock options covering 75,000 PTGX shares at a conversion price of $21.58 per share. These options are fully vested and expire on October 11, 2026. After the exercise, 225,000 options remain outstanding according to the derivative holdings table.

What does the Form 4/A amendment for PTGX clarify about the original filing?

The amendment clarifies that all reported transactions were conducted under a Rule 10b5-1 plan adopted on January 30, 2026. It also corrects the previously unchecked 10b5-1 box, ensuring the filing accurately reflects the pre-planned nature of the CEO’s trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/14/2026 - 08:06 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PATEL DINESH V PH D

(Last)

(First)

(Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK

CALIFORNIA

94560-1160

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
05/12/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/12/2026		M⁽¹⁾		75,000	A	$21.58	598,478	D
Common Stock	05/12/2026		S		75,000	D	$100.12⁽²⁾	523,478	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$21.58	05/12/2026		M			75,000	⁽³⁾	10/11/2026	Common Stock	75,000	$0.00	225,000	D

Explanation of Responses:

1. This Form 4 Amendment is being filed to clarify that the transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026 and to check the appropriate box which appeared unchecked on the original Form 4 filing.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.83 to $103.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. These stock options are fully vested and will expire on October 11, 2026.

	/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR